INVA-8001 Market Summary

Key Factors Driving INVA-8001 Growth

1. Novel Mast Cell–Targeted Mechanism Addresses a Validated Disease Pathway

Mast cells play a central role in chronic urticaria, atopic dermatitis, and pruritic skin disorders. INVA-8001 selectively inhibits chymase, which activates stem cell factor (SCF) signaling and promotes mast-cell survival and proliferation.

Preclinical studies demonstrated:

• Approximately 100% inhibition of chymase activity.
• Approximately 82% reduction in mast-cell activation (CD63+ cells).
• Approximately 95% reduction in tryptase release, a key marker of mast-cell degranulation.

This mechanism may offer a differentiated approach compared with anti-IgE antibodies or KIT-targeting therapies by modulating mast-cell activity without broadly suppressing the immune system.

2. Oral Administration Could Provide a Significant Competitive Advantage

Most advanced therapies for chronic urticaria and related allergic diseases are injectable biologics.

INVA-8001 is:

• Orally administered.
• Once-daily dosing.
• Small-molecule based.

An effective oral alternative could appeal to patients seeking to avoid injections and may improve treatment accessibility and adherence. The convenience advantage is particularly relevant in chronic diseases requiring long-term therapy.

3. Large Unmet Need in Chronic Urticaria and Pruritic Diseases

The company's current development focus is centered on:

• Chronic inducible urticaria (CIndU)
• Chronic spontaneous urticaria (CSU)
• Prurigo nodularis

A substantial proportion of patients remain symptomatic despite antihistamines, while biologics are often reserved for later lines of therapy. The continuing demand for additional treatment options is reflected by the success of newer biologics targeting IgE, IL-4/IL-13, IL-31, and KIT pathways.

If INVA-8001 demonstrates clinically meaningful efficacy, it could potentially be positioned earlier in the treatment algorithm because of its oral administration and targeted mechanism.

4. Favorable Historical Safety Data

Prior studies conducted by Daiichi Sankyo evaluated INVA-8001 in healthy volunteers and patients.

Key findings included:

• No dose-limiting toxicities.
• No treatment-related serious adverse events.
• No clinically significant ECG or vital-sign abnormalities.
• Predominantly mild adverse events across single-ascending-dose and multiple-ascending-dose studies.

A favorable safety profile is particularly important in chronic dermatologic and allergic diseases where long-term treatment is often required.

5. Broad Expansion Potential Across Multiple Mast Cell–Driven Diseases

Beyond urticaria, the company has identified several additional diseases where mast-cell activation contributes to pathology:

• Atopic dermatitis
• Prurigo nodularis
• Indolent systemic mastocytosis
• Eosinophilic gastrointestinal disorders
• Primary sclerosing cholangitis
• Other inflammatory and fibrotic disorders

The broad biological role of chymase creates multiple lifecycle-expansion opportunities if proof-of-concept is established in early indications.

INVA-8001 Recent Developments

In January 2026, Invea Therapeutics, a clinical-stage biotech developing oral small molecules for inflammatory diseases, announced terms for its initial public offering on Wednesday, according to Renaissance Capital.

The Guilford, CT-based firm plans to raise USD 35 million by offering 3.2 million shares at USD 10–USD 12 each, valuing the company at USD 127.5 million at the midpoint.

Its lead candidate, INVA8001, targets chronic inducible urticarial with a planned Phase IIa clinical trial in the EU; INVA8003 is in preclinical development.

“INVA-8001 Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of INVA-8001 for potential indication like Atopic dermatitis, Chronic urticaria, and Prurigo nodularis in the 7MM. A detailed picture of INVA-8001’s existing usage in anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the INVA-8001 for potential indications. The INVA-8001 market report provides insights about INVA-8001’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current INVA-8001 performance, future market assessments inclusive of the INVA-8001 market forecast analysis for potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of INVA-8001 sales forecasts, along with factors driving its market.

INVA-8001 Drug Summary

INVA-8001 (formerly ASB17061) is an investigational oral small-molecule chymase inhibitor being developed by Invea Therapeutics for the treatment of immune-mediated inflammatory diseases, including moderate-to-severe Atopic Dermatitis, Chronic Urticaria, and Prurigo Nodularis. The drug selectively inhibits chymase, a mast cell-derived serine protease involved in inflammation, epithelial barrier damage, fibrosis, and activation of the stem cell factor (SCF)-c-KIT signaling pathway that promotes mast cell survival and proliferation. By targeting this pathway, INVA-8001 aims to reduce mast cell-driven inflammation without causing broad immunosuppression or mast cell depletion, potentially offering a differentiated safety profile compared with existing therapies. Administered orally once daily, the drug has demonstrated favorable pharmacokinetic properties and tolerability in preclinical and early clinical studies and is being evaluated as a convenient systemic treatment option for patients with chronic inflammatory and allergic disorders. The report provides INVA-8001’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the INVA-8001 Market Report

The report provides insights into:

• A comprehensive product overview including the INVA-8001 MoA, description, dosage and administration, research and development activities in potential indication like Atopic dermatitis, Chronic urticaria, and Prurigo nodularis.
• Elaborated details on INVA-8001 regulatory milestones and other development activities have been provided in INVA-8001 market report.
• The report also highlights INVA-8001‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in potential indications across the United States, Europe, and Japan.
• The INVA-8001 market report also covers the patents information, generic entry and impact on cost cut.
• The INVA-8001 market report contains current and forecasted INVA-8001 sales for potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The INVA-8001 market report also features the SWOT analysis with analyst views for INVA-8001 in potential indications.

Methodology

The INVA-8001 market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

INVA-8001 Analytical Perspective by DelveInsight

• In-depth INVA-8001 Market Assessment

This INVA-8001 sales market forecast report provides a detailed market assessment of INVA-8001 for potential indication like Atopic dermatitis, Chronic urticaria, and Prurigo nodularis in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted INVA-8001 sales data uptil 2034.

• INVA-8001 Clinical Assessment

The INVA-8001 market report provides the clinical trials information of INVA-8001 for potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

INVA-8001 Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

INVA-8001 Market Potential & Revenue Forecast

• Projected market size for the INVA-8001 and its key indications
• Estimated INVA-8001 sales potential (INVA-8001 peak sales forecasts)
• INVA-8001 Pricing strategies and reimbursement landscape

INVA-8001 Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• INVA-8001 Market positioning compared to existing treatments
• INVA-8001 Strengths & weaknesses relative to competitors

INVA-8001 Regulatory & Commercial Milestones

• INVA-8001 Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

INVA-8001 Clinical Differentiation

• INVA-8001 Efficacy & safety advantages over existing drugs
• INVA-8001 Unique selling points

INVA-8001 Market Report Highlights

• In the coming years, the INVA-8001 market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The INVA-8001 companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence INVA-8001’s dominance.
• Other emerging products for Atopic dermatitis, Chronic urticaria, and Prurigo nodularis are expected to give tough market competition to INVA-8001 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of INVA-8001 in potential indications.
• Analyse INVA-8001 cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted INVA-8001 sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of INVA-8001 in potential indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of INVA-8001? How strong is INVA-8001’s clinical and commercial performance?
• What is INVA-8001’s clinical trial status in each individual indications such as Atopic dermatitis, Chronic urticaria, and Prurigo nodularis and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the INVA-8001 Manufacturers?
• What are the key designations that have been granted to INVA-8001 for potential indications? How are they going to impact INVA-8001’s penetration in various geographies?
• What is the current and forecasted INVA-8001 market scenario for potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of INVA-8001 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to INVA-8001 for potential indications?
• Which are the late-stage emerging therapies under development for the treatment of potential indications?
• How cost-effective is INVA-8001? What is the duration of therapy and what are the geographical variations in cost per patient?